Table 5. Risk of hypoprothrombinemia or hemorrhagic events associated with use of individual study antibiotics.
| Cases | Controls | Crude OR (95% CI) | p-value | Adjusted OR*(95% CI) | p-value | |
|---|---|---|---|---|---|---|
| (N = 704) | (N = 2816) | |||||
| Reference antibiotics | 433 | 2042 | Reference | Reference | ||
| Cefmetazole | 67 | 130 | 2.46 (1.80–3.36) | <0·0001 | 2.88 (2.08–4.00) | <0·0001 |
| Flomoxef | 169 | 586 | 1.39 (1.13–1.71) | 0·002 | 1·35 (1.09–1·67) | 0.006 |
| Cefoxitin | 6 | 31 | 0.85 (0.34–2.11) | 0.73 | 0.83 (0.33–2.08) | 0.69 |
| Cefoperazone | 29 | 27 | 4.93 (2.89–8·41) | <0·0001 | 4.57 (2.63–7.95) | <0·0001 |
*adjusted by use of anticoagulants, drugs for liver failure, and drugs for chronic viral hepatitis, occurrence of hemorrhagic events, and poor nutritional status within 6 months prior to the index date, and severity of illness calculated by PBDI